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Coate KC, Kraft G, Moore MC, Smith MS, Ramnanan C,
Irimia JM, Roach PJ, Farmer B, Neal DW, Williams P, Cher-
rington AD. Hepatic glucose uptake and disposition during short-
term high-fat vs. high-fructose feeding. Am J Physiol Endocrinol
Metab 307: E151–E160, 2014. First published May 27, 2014;
doi:10.1152/ajpendo.00083.2014.—In dogs consuming a high-fat and
-fructose diet (52 and 17% of total energy, respectively) for 4 wk,
hepatic glucose uptake (HGU) in response to hyperinsulinemia, hy-
perglycemia, and portal glucose delivery is markedly blunted with
reduction in glucokinase (GK) protein and glycogen synthase (GS)
activity. The present study compared the impact of selective increases
in dietary fat and fructose on liver glucose metabolism. Dogs con-
sumed weight-maintaining chow (CTR) or hypercaloric high-fat
(HFA) or high-fructose (HFR) diets diet for 4 wk before undergoing
clamp studies with infusion of somatostatin and intraportal insulin
(3–4 times basal) and glucagon (basal). The hepatic glucose load
(HGL) was doubled during the clamp using peripheral vein (Pe)
glucose infusion in the first 90 min (P1) and portal vein (4
mg·kg1·min1) plus Pe glucose infusion during the final 90 min
(P2). During P2, HGU was 2.8  0.2, 1.0  0.2, and 0.8  0.2
mg·kg1·min1 in CTR, HFA, and HFR, respectively (P  0.05 for
HFA and HFR vs. CTR). Compared with CTR, hepatic GK protein
and catalytic activity were reduced (P  0.05) 35 and 56%, respec-
tively, in HFA, and 53 and 74%, respectively, in HFR. Liver glycogen
concentrations were 20 and 38% lower in HFA and HFR than CTR
(P 0.05). Hepatic Akt phosphorylation was decreased (P 0.05) in
HFA (21%) but not HFR. Thus, HFR impaired hepatic GK and
glycogen more than HFA, whereas HFA reduced insulin signaling
more than HFR. HFA and HFR effects were not additive, suggesting
that they act via the same mechanism or their effects converge at a
saturable step.
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insulin signaling
EXCESS CONSUMPTION OF DIETARY FAT and fructose or sucrose, in
what has been commonly referred to as a “Western” diet, has
been suggested to play a role in the obesity and diabetes
epidemic within the US (47–49). High fat and fructose intakes
are associated with the development of impaired glucose tol-
erance (IGT) (e.g., see Refs. 2, 10, and 42), suggesting that the
liver is a key target of these diets. Failure of the liver to
transition from net output to uptake of glucose is associated
with the development of IGT and hyperglycemia (5, 30).
Unfortunately, hepatic glucose uptake (HGU) is difficult, if not
impossible, to quantify in the human and many animal models
because of the invasiveness of the procedures required and the
difficulty in cannulating the hepatic vasculature. The dog has
proven to be a useful model for examination of HGU and
postprandial metabolism (reviewed in Ref. 34).
In the dog, 4 wk of high-fat plus high-fructose feeding
[high-fat and -fructose diet (HFFD)] impairs glucose tolerance
and renders the liver resistant to the stimulatory effects of
hyperinsulinemia, hyperglycemia, and portal glucose delivery
on HGU and glycogen synthesis (10). Two enzymes especially
important to those processes are hepatic glucokinase (GK), the
rate-determining enzyme in HGU, and glycogen synthase
(GS), which is required for storage of the glucose taken up by
the liver. Previously, we demonstrated that 4 wk of HFFD in
dogs is associated with diminished GK and GS activity, im-
paired HGU, and reduced glycogen synthesis during a hyper-
insulinemic hyperglycemic clamp in the presence of portal
glucose delivery (the portal glucose signal) (9). However, we
cannot ascertain from those data whether excess dietary fat,
fructose, or both are required to elicit aberrant hepatic glucose
flux under conditions that mimic the postprandial state. To
form a basis for further study and eventually translate the
knowledge into public health measures, it is important to
separate the effects of fat vs. fructose. Thus, the aim of this
study was to determine which macronutrient (fat or fructose) is
the primary contributor to metabolic dysfunction seen after 4
wk of feeding or whether both are required.
RESEARCH DESIGN AND METHODS
Animal Care and Surgical Procedures
The protocol was approved by the Vanderbilt University Institu-
tional Animal Care and Use Committee, and the animals were housed
and cared for according to Association for Assessment and Accredi-
tation of Laboratory Animal Care guidelines. Adult male mongrel
dogs (n  5/group) were fed a meat/laboratory chow diet [control
(CTR); Kal Kan, Franklin, TN, and PMI Nutrition LabDiet, Rich-
mond, IN], a high-fat diet (HFA; TestDiet, Richmond, IN), or a
high-fructose diet (HFR; TestDiet) once daily for 4 wk (Table 1). The
dogs in the CTR group were fed amounts calculated to achieve weight
maintenance. The percentage of energy provided as fructose in the
HFR was chosen to approximate the 90th percentile of fructose
intakes among US adults and adolescents (51), and the fat and
saturated fat percentage contents of the HFA diet were 95th per-
centile for individuals 1 yr of age in the US (3). Energy consump-
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tion of dogs in HFA and HFR was matched, but both groups were
hypercaloric relative to CTR (Fig. 1).
Experimental Design
After 4 wk of experimental diet feeding, hyperinsulinemic hyper-
glycemic (HIHG) clamp experiments were conducted on conscious
dogs following an 18-h fast. Just prior to beginning the fast, each dog
was fed a can of meat to ensure equivalent energy and macronutrient
consumption among groups on the day before study. Each experiment
consisted of a 100-min equilibration period (120 to 20 min), a
20-min period for basal sampling (20 to 0 min), and a 180-min
experimental period divided into two subperiods (P1, 0–90 min; P2,
90–180 min). At 120 min, a priming dose of [3-3H]glucose (38
Ci) was delivered, and a constant infusion of [3-3H]glucose (0.38
Ci/min) was initiated. At time 0, a constant peripheral venous
infusion of somatostatin (0.8 g·kg1·min1) was begun, and insulin
and glucagon were infused intraportally at three to four times basal
(1.2 mU·kg1·min1) and basal (0.55 ng.kg1.min1) rates, respec-
tively. A variable peripheral infusion of 50% dextrose was also begun
to double the hepatic glucose load (HGL). In P2, 20% dextrose was
infused intraportally at 4.0 mg·kg1·min1, and the peripheral glu-
cose infusion rate was reduced at the same time so that HGL was
equivalent during P1 and P2. Throughout P1 and P2, the arterial
glucose concentrations were analyzed at 5-min intervals, and the
peripheral glucose infusion rate was adjusted as necessary to maintain
comparable concentrations in all animals and to maintain the HGL at
a stable level within each animal. At the end of the study, each animal
was anesthetized with pentobarbital sodium, whereas all infusions
were continued, and liver tissue was freeze-clamped in situ and stored
at 80°C for later analysis. Then the animal was euthanized.
Analyses
Real-time PCR and western blotting. RNA isolation, cDNA syn-
thesis, quantitative PCR primers and analysis, and Western blotting
procedures were performed as described previously (13, 41). The GK
antibody was a gift from Dr. Masakazu Shiota (Vanderbilt University
School of Medicine). All other antibodies were purchased from Santa
Cruz Biotechnology [actin and GK regulatory protein (GKRP)] or
Cell Signaling Technology [phosphorylated Akt (Ser473) and GSK-
3]. Test protein bands were quantified using ImageJ software (http://
rsb.info.nih.gov/ij/), and all were normalized to actin.
Enzyme activity. GK activity was assessed as described previously
(4). GS activity ratio was calculated as activity measured at low
glucose 6-phosphate (G6P; 160 M) vs. high G6P (6.7 mM) concen-
trations [GS-(L/H) ratio of low to high G6P], with low UDP glucose
(134 M) (23). Glycogen phosphorylase (GP) activity was assessed
by measuring the incorporation of [14C]glucose from [14C]glucose
1-phosphate into glycogen in the absence or presence of 2 mM
AMP (20). G6P concentrations were determined by the method of
Michal (33).
Biochemicals. Plasma glucose, [3H]glucose, glucagon, insulin, and
nonesterified fatty acid (NEFA) levels and blood lactate and glycerol
concentrations were measured using standard methods, as described
previously (19, 36). Liver glycogen levels were determined by the
method of Keppler and Decker (26).
Hepatic tissue lipids were extracted using the method of Folch et al.
(16) and separated by thin-layer chromatography using Silica Gel 60
A plates developed in petroleum ether, ethyl ether, and acetic acid
(80:20:1) and visualized by rhodamine 6G. Individual lipid classes
were scraped from the plates and methylated using BF3/methanol, as
described by Morrison and Smith (37). The methylated fatty acids
were extracted and analyzed by gas chromatography, with dipentade-
canoyl phosphatidylcholine (C15:0), diheptadecanoin (C17:0), triei-
cosenoin (C20:1), and cholesteryl eicosenoate (C20:1) used as stan-
dards.
Calculations
Unidirectional HGU was calculated by multiplying the hepatic
fractional extraction of [3H]glucose by the HGL (mg·kg1·min1), as
described previously (9). It should be stressed that this approach
yields HGU rather than net HGU. Net hepatic substrate balances, net
hepatic carbon retention, and nonhepatic glucose uptake (non-HGU)
were calculated with the arteriovenous difference method, as de-
scribed previously (10). Non-HGU is the difference between the
glucose infusion rate (GIR) and net hepatic glucose balance (NHGB),
adjusted for change in the size of the glucose pool, as described
previously (52). An indirect method was utilized for calculation of
NHGB, comprised of net hepatic glucose output (NHGO) and uptake
(NHGU), to reduce any error introduced by streaming of infusate in
the portal vein (10). Thus, HGU and NHGU provide independent
assessments of liver glucose uptake, both of which have inherent
noise. Attributing meaning to their differences is thus not useful.
Tracer-determined glucose disappearance (Rd) was calculated from
isotope dilution (50). Plasma insulin and glucagon levels entering the
hepatic sinusoids were calculated as described elsewhere (13). The
incorporation of glucose into glycogen through the direct pathway
was calculated by dividing hepatic 3H-labeled glycogen by the aver-
age inflowing plasma [3H]glucose-specific radioactivity (44).
Fig. 1. Mean daily energy intake. Daily energy intake was recorded in dogs fed
a control (CTR), a high-fat (HFA), or a high-fructose (HFR) diet for 4 wk. Data
are means  SE; n  5/group. Dogs fed the HFA or HFR diets were provided
isoenergetic quantities of their respective diets over the course of 4 wk, but
both groups were hypercalorically fed relative to CTR dogs.
Table 1. Macronutrient composition of diets
%Total Energy
Macronutrient CTR HFA HFR
Protein 31 22 26
Fat (total) 26 52 26
Saturated fat 11* 23 11
Monounsaturated fat 10* 22 11
Polyunsaturated fat 4* 7 4
Carbohydrate (total) 43 26 48
Starch 41 21 24
Glucose 0.1 0.1 0.1
Fructose 0.1 0.1 17
Sucrose 1.3 0.1 0.1
Lactose 0.1 0.1 0.1
CTR, chow and meat control diet; HFA, high-fat diet; HFR, high-fructose
diet. *Values are approximate; information not available from the manufac-
turer of the meat in the diet.
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Statistical Analyses
All data are presented as means  SE. Mean values for P1 or P2
are the means for the last hour of each period. Two-way analysis of
variance with or without repeated-measures design was used
(SigmaStat; Systat, Richmond, CA), and post hoc analysis was per-
formed using the Student-Newman-Keuls multiple-comparisons test.
Significance was established when P was 0.05.
RESULTS
Weight Change
Body weights at the beginning of dietary intervention were
not different among the groups (24.9  1.6, 24.9  0.8, and
25.9  1.0 kg in CTR, HFA, and HFR, respectively). The
cumulative weight changes during the 4 wk of dietary inter-
vention were 0.8  0.4, 2.2  0.5, and 1.6  0.5 kg,
respectively (P  0.005 for HFA and HFR vs. CTR).
Plasma Hormone Concentrations
Fasting arterial plasma insulin levels were increased in HFR
and HFA (70 and 55%, respectively, P 0.05) relative to CTR
(mean of the values in the basal period: 8.0  1.6, 13.6  1.2,
and 12.4  1.6 U/ml in CTR, HFR, and HFA, respectively;
Fig. 2). Consistent with this, arterial plasma C-peptide concen-
trations tended to be elevated in HFR and HFA (0.36 0.0 and
0.43  0.08 ng/ml, respectively, vs. 0.23  0.03 ng/ml in
CTR; P  0.15 and 0.08). There was no effect of diet on
fasting arterial plasma glucagon levels. During the HIHG
clamp, arterial and hepatic sinusoidal insulin concentrations
increased similarly (3- to 4-fold basal) in all groups, and
arterial and hepatic sinusoidal glucagon concentrations re-
mained basal (Fig. 2).
Blood Glucose, HGL, and HGU
Fasting blood glucose concentrations did not differ among
groups during the basal period. During P1, arterial blood
glucose concentrations were increased to 	163 mg/dl in all
groups (P  0.05 vs. basal period) to double the HGL (Fig. 3).
During P2, arterial blood glucose was clamped at a slightly
reduced concentration (	150 mg/dl) to maintain a doubling of
the hepatic glucose load in the presence of intraportal glucose
infusion. The portal blood glucose concentrations in the three
groups averaged 	160 and 165 mg/dl during P1 and P2,
respectively, such that the arterial-portal glucose gradient (mg/
dl) was 3 in P1 and 15 in P2. Total hepatic blood flow was
similar among groups under basal conditions and throughout
the clamp (data not shown).
Basal HGU averaged 0.2–0.5 mg·kg1·min1 in all groups
(Fig. 3). Combined hyperinsulinemia and hyperglycemia stim-
ulated an increase in HGU and CTR, with a mean rate of 1.7 
0.3 mg·kg1·min1 during the last hour (steady-state period) of
P1 (P  0.05 vs. basal period). Delivery of glucose into the
portal vein augmented HGU even further (mean of 2.8  0.3
mg·kg1·min1 during the last hour of P2; Fig. 3). In contrast,
both high-fat and high-fructose feeding for 4 wk impaired the
liver’s response to the stimulatory effects of combined hyper-
insulinemia, hyperglycemia, and portal glucose delivery on
HGU. Whereas the mean rate of HGU in HFA during P1 (1.0 0.3
mg·kg1·min1) did not differ significantly from that in CTR,
the rate in HFR (0.6  0.2 mg·kg1·min1) was significantly
Fig. 2. Plasma hormone concentrations during
hyperinsulinemic hyperglycemic (HIHG) clamps.
Arterial plasma insulin (A) and glucagon (B)
and hepatic sinusoidal insulin (C) and glucagon
(D) during basal (20 to 0 min) and experi-
mental periods (0–180 min) of HIHG clamps in
CTR (▫), HFA (Œ), or HFR (Œ) diet groups. Po,
portal. Data are means  SE; n  5/group.
*P  0.05, CTR vs. other groups.
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less than in CTR (Fig. 3). In the presence of portal glucose
delivery (P2), on the other hand, both groups displayed signif-
icantly lower rates of HGU relative to CTR. This was due to
further stimulation of HGU during P2 in CTR and the lack of
such an effect in both HFA and HFR.
Basal rates of tracer-determined hepatic glucose production
(HGP) were very similar among all groups (	2.2 mg·
kg1·min1). During P1, HGP was quickly and fully sup-
pressed in CTR (averaging only 0.2  0.3 mg·kg1·min1
during the last hour of P1), but it was less suppressed in the
other groups (to 1.0 0.4 and 1.3 0.2 mg·kg1·min1 in the
HFA and HFR groups, respectively; P  0.09 and P  0.01,
respectively, vs. CTR). During P2, HGP in was zero in all
groups, with no significant differences among groups (data not
shown).
During the basal period, all groups were in a state of net hepatic
glucose output (Fig. 3). The CTR group switched to NHGU
within 30 min of the start of the HIHG clamp, and intraportal
glucose delivery during P2 enhanced NHGU 2.1 mg·kg1·min1
over the rate observed in P1. During P1, NHGO in HFA was
rapidly and fully suppressed (with NHGO reaching 0.1  0.1
mg·kg1·min1 during the last hour of P1). The addition of portal
glucose delivery during P2 increased NHGU by 1.7  0.2
mg·kg1·min1, an increment not significantly different from that
in the CTR group. Thus the enhancement of NHGU by the
glucose portal signal appeared intact. Nevertheless, the actual rate
of NHGU in HFA was significantly blunted compared with CTR
during both P1 and P2. In the HFR group, NHGO was not fully
suppressed during P1 (0.8  0.2 mg·kg1·min1), and the group
only exhibited NHGU of 0.8 0.3 mg·kg1·min1 during the last
hour of P2 (P  0.01 vs. CTR group). Thus the response to the
portal glucose signal was lost.
The peripheral venous GIR required to maintain hypergly-
cemia did not differ significantly among groups, probably
because of the large variance in the response of the CTR
animals, and there were no significant differences among the
groups in either non-HGU or tracer-determined Rd (Table 2).
Rd was numerically higher in CTR than in the other two groups
(P 0.3 for both groups vs. CTR), whereas non-HGU was not;
thus the trend toward a higher Rd in CTR was consistent with
the greater liver glucose uptake in that group.
Lactate Metabolism
All groups exhibited similar arterial blood lactate concen-
trations and rates of net hepatic lactate uptake (NHLU) under
basal conditions (Fig. 4). In the CTR and HFA groups, hyper-
insulinemia and hyperglycemia elicited an increase in arterial
blood lactate levels coincident with a switch from NHLU to
output (NHLO), although NHLO was significantly lower in
HFA vs. CTR. In contrast, arterial blood lactate levels were not
significantly elevated from basal during either test period in
HFR, and these animals exhibited NHLU for the entire study
(P  0.05 vs. CTR and HFA).
Glycerol, NEFA, and Triglyceride Metabolism
During the basal period, arterial blood glycerol concentra-
tions were significantly elevated in HFA and HFR vs. CTR,
Fig. 3. Arterial blood glucose (A), hepatic glucose load (HGL; B), unidirectional hepatic glucose uptake (HGU; C and D), and net hepatic glucose balance
(NHGB; E and F) in CTR (▫), HFA (Œ), and HFR (Œ) during the basal (20 to 0 min) and experimental periods (0 –180 min) of HIHG clamps. Data are
means  SE; n  5/group. *P  0.05 vs. CTR.
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whereas net hepatic glycerol uptake was significantly higher
only in HFR (Fig. 4). Fasting arterial plasma NEFA concen-
trations and net hepatic NEFA uptakes were not different
among groups. Glycerol and NEFA concentrations declined in
response to hyperinsulinemia in all groups, but the glycerol
concentrations remained higher in the HFA and HFR groups
than in CTR during the clamp. The net hepatic uptake rates of
glycerol and NEFA decreased in parallel to the changes in their
circulating concentrations and were not different in either HFA
or HFR vs. CTR during P1 or P2 (Fig. 4).
Fasting plasma total triglyceride concentrations did not differ
among diet groups (1,156  284, 1,165  156, and 1,148  28
mol/l in CTR, HFA, and HFR, respectively, P  0.8).
Likewise, terminal liver triglyceride levels were not statisti-
cally different among groups (g/mg liver: CTR 1.6  0.2,
HFA 2.0 0.3, and HFR 1.8 0.2; P0.4). Additionally, the
predominant fatty acid species in liver triglycerides in all
groups was 18:1 (35–40%), followed by 18:2 (22–28%) and
16:0 (20–22%), with no differences in lipid species among
groups.
Hepatic GK and GKRP
Relative hepatic GK mRNA expression in hepatic biopsies
taken at the end of study was not significantly different among
groups. GK protein content and its catalytic activity were
reduced by 43 and 56%, respectively, in HFA vs. CTR (P 
0.05; Fig. 5). In HFR, GK protein content and activity were
reduced even further (58 and 74%, respectively, P  0.05 vs.
CTR and HFA). There was also a significant but more modest
decrease in GKRP protein (Fig. 5).
Hepatic Insulin Signaling and Glycogen Metabolism
The phosphorylation of Akt was significantly lower (21%) in
HFA compared with CTR, whereas there was only a minor
(9%) and nonsignificant decline in HFR (Fig. 5). In keeping
with this, the fractional activity ratio (active/total) of GS was
reduced by 50 and 25% in HFA and HFR, respectively,
although only HFA was statistically different (P  0.05) from
CTR (Fig. 6). On the other hand, the activity ratio of GP tended
to be elevated by the dietary modifications (140 and 51%
greater than CTR in HFA and HFR, respectively; P 0.06 and
0.05, respectively, vs. CTR). When the activity ratios of GS
and GP were themselves expressed as a ratio, they were
significantly lower in both HFA (0.26) and HFR (0.61) than in
CTR (1.26), although there were no significant differences in
HFA and HFR vs. CTR with regard to total activity of either
enzyme. Moreover, terminal liver glycogen levels were signif-
icantly lower in HFR and tended to be lower in HFA than in
CTR (Fig. 6). Net hepatic carbon retention, an indicator of net
hepatic glycogen synthesis, followed the same pattern as ter-
minal glycogen concentrations [9.8  1.0, 5.9  1.7, and 3.7 
1.1 mg/g liver in CTR, HFA, and HFR, respectively (P  0.09
and 0.004 vs. CTR)]. Likewise, the incorporation of glucose
into glycogen through the direct synthetic pathway (glucose ¡
glucose 6-phosphate ¡ glucose 1-phosphate ¡ UDP-glucose
¡ glycogen) was markedly decreased in both HFR and HFA
(78 and 62%, respectively, P  0.05 vs. CTR), with the
reduction being significantly greater in HFR than in HFA (Fig.
6). Hepatic G6P did not differ significantly among groups (71 12,
63  8, and 85  17 nmol/g liver in CTR, HFA, and HFR,
respectively). The phosphorylation of GSK-3 was also simi-
lar among groups (relative protein: 1.00  0.04, 0.97  0.09,
and 1.01  0.06 in CTR, HFA, and HFR, respectively).
DISCUSSION
Numerous studies have described the adverse metabolic
effects of high dietary fat (27–29, 43) or fructose (39, 40, 46)
on whole body insulin action and hepatic glucose metabolism;
however, most of those studies were conducted under hyper-
insulinemic euglycemic conditions in which the liver was only
a minor contributor to whole body glucose disposal and the
liver’s ability to take up glucose was not evaluated. In the
current studies, we utilized conditions that normally stimulate
liver glucose uptake and found that either a high-fat or a
high-fructose diet significantly impaired HGU and NHGU in
response to the combination of hyperinsulinemia and hyper-
glycemia, with or without portal glucose delivery. In the HFR
group, not only was NHGU markedly blunted in response to
the combination of hyperinsulinemia and hyperglycemia
brought about with peripheral glucose infusion (P1), but also,
the enhancement of NHGU in response to the portal glucose
delivery (P2) was lost. In the HFA group, NHGU during P1
was significantly reduced compared with CTR, but the en-
hancement of NHGU in response to portal glucose delivery
remained intact. Nevertheless, because of the blunting of
NHGU during P1, the rate of NHGU during P2 remained
significantly reduced in HFA compared with CTR.
In our previous study using a diet high in both fat and
fructose (HFFD) carried out under conditions similar to these,
we observed that the HFFD was associated with the loss of the
enhancement of NHGU in response to the portal glucose signal
as well as a marked reduction in GK protein and in activation
of GS compared with the weight-maintaining control diet (9).
Our primary goal in the current studies was to determine which
of the dietary components, fat or fructose, was most responsi-
ble for the defects or whether they had additive effects. For this
reason, we compared the HFA and HFR diets to the same CTR
Table 2. Rates of glucose infusion, nonhepatic glucose
uptake, and glucose Rd
Experimental Period
Group Basal Period Period 1 (PoG) Period 2 (
PoG)
Total glucose infusion rate, mg·kg1·min1
CTR 0.0  0.0 9.0  3.0 10.2 2.4
HFA 0.0  0.0 5.7  0.8 8.4 1.2
HFR 0.0  0.0 4.9  0.6 8.5 1.2
Nonhepatic glucose uptake, mg·kg1·min1
CTR 1.7  0.2 6.8  2.1 6.3 2.4
HFA 1.8  0.2 5.7  0.6 6.4 1.0
HFR 2.0  0.1 5.9  0.5 7.2 1.0
Glucose Rd, mg·kg1·min1
CTR 2.5  0.2 7.1  1.6 9.0 2.0
HFA 2.7  0.2 6.4  0.5 7.7 1.0
HFR 2.6  0.2 6.1  0.4 7.8 1.0
Values are means SE; n 5/group. Rd, glucose disappearance;PoG, no
portal glucose;
PoG, portal glucose infusion. The glucose infusion rate (GIR)
during period 2 is the sum of the portal and peripheral GIRs; the portal GIR
was 4 mg·kg1·min1 in all groups. There were no significant differences
among groups.
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diet we used previously. However, this means that we have not
examined the effect of overfeeding per se on the liver, and it
would interesting in the future to examine animals given an
excess of the chow diet.
GK Protein and Activity
In our previous investigation comparing chow-fed control
dogs and those receiving HFFD (9), which followed a protocol
identical to the current one, we also collected hepatic tissue
under basal conditions (euglycemia and euinsulinemia) from
dogs that did not undergo the study so that we could examine
the increases in GK that occurred during the clamp. In both the
CTR and HFFD dogs in that investigation, GK mRNA in-
creased 	24-fold above basal by the end of P2. However, the
ability of the portal glucose signal to increase both GK protein
and activity was abolished by the HFFD. Similarly, in the
current investigation, the increase in GK mRNA caused by
hyperinsulinemia, hyperglycemia, and the portal glucose signal
(	24-fold) was not impacted significantly by either the HFA or
HFR diets. Additionally, both diets suppressed GK protein and
activity, suggesting that they also abolished the ability of portal
glucose delivery to increase the activity of GK, the rate-
limiting enzyme for hepatic glucose utilization (15). In fact, the
decrease in GK activity in HFR relative to CTR was equivalent
in magnitude to the decrease observed previously in dogs fed
a combination of high fat and fructose (9). Thus, as was true for
HGU, the effects of high dietary fat and fructose on hepatic GK
activity were not additive, with a saturable effect being seen in
response to a selective physiological increase in dietary fruc-
tose alone. Furthermore, the differences in GK protein among
groups mirrored the differences in HGU and net hepatic lactate
balance (see below), underscoring the fact that GK serves a
critical function in facilitating the normal response of the liver
to elevated glucose and insulin.
Hepatic GK mRNA expression is dependent on insulin (24,
31), and the higher basal insulin concentrations in the HFA and
HFR groups, relative to CTR, likely helped sustain GK mRNA
expression in those groups. A significant decline in GK protein
Fig. 4. Arterial blood lactate (A) and glycerol
(C) and plasma nonesterified fatty acid
(NEFA; E) concentrations and net hepatic
balances of lactate (B), glycerol (D), and
NEFA (F) during basal (20 to 0 min) and
experimental periods (0–180 min) of HIHG
clamps in CTR (▫), HFA (Œ), and HFR (Œ)
diet groups. Data are means  SE; n 
5/group. *P  0.05, CTR vs. other groups;
**P 0.05, HFR vs. other groups; †P 0.05,
HFA vs. CTR; ‡P  0.05, HFR vs. CTR.
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content in HFA and HFR vs. CTR in the absence of a
difference between groups in relative GK expression suggests
either that the translation of GK mRNA was impaired or that
the turnover (degradation) of GK protein was enhanced. Al-
though rodent studies have generally shown that hepatic GK
mRNA, as well as protein and activity, are reduced by high-fat
feeding (11, 12, 25, 38), these findings are not universal (21,
53). Gorman et al. (21) reported an actual increase in hepatic
GK mRNA in wild-type mice on a high-fat vs. chow diet.
Additionally, the effect of high-fructose feeding on hepatic GK
activity is unclear. Bizeau et al. (6) demonstrated a significant
decrease in GK activity in primary cultures of periportal
hepatocytes isolated from rats that were fed a high-sucrose diet
(in which 35% of the energy was derived from fructose) for 1
wk. Conversely, liver GK activity was increased in rats that
consumed 10% fructose in their drinking water for 3 wk (17,
18), although they also exhibited impaired glucose tolerance,
fasting hyperglycemia, hyperinsulinemia, hypertriglyceride-
mia, and increased liver triglyceride content. Thus, it is diffi-
cult to ascertain whether excess fructose per se contributed to
modulation of liver GK activity in that study. In the present
study, hepatic GKRP content was significantly reduced only in
Fig. 5. Hepatic glucokinase (GK) and glucokinase regulatory protein (GKRP) and phosphorylated (p)-Akt, a marker of insulin signaling. Levels of GK mRNA
(A), protein (B), and activity (C), GKRP protein (D), and p-Akt on Ser473 (E) in CTR (open bars), HFA (black bars), and HFR (hatched bars) groups. All proteins
are expressed relative to tissue actin, and data for the HFA and HFR groups are normalized to those in CTR. Data are means  SE; n  5/group. Groups with
the same letters are not significantly different from each other; where there are no letters, there are no significant differences among groups.
Fig. 6. Markers of hepatic glycogen metabolism. Activity ratios of glycogen synthase (GS; A) and glycogen phosphorylase (GP; B), terminal liver glycogen
concentrations (C), and glycogen synthesized via the direct pathway (D) for CTR (open bars), HFA (black bars), and HFR (hatched bars). Data are means 
SE; n  5/group. Groups with the same letters are not significantly different from one another; where there are no letters, there are no significant differences
among groups. L/H, ratio of low to high glucose 6-phosphate.
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HFR dogs, although it tended to be lower in the HFA group
than in CTR. GKRP is thought to exert a permissive effect on
GK protein content by protecting it from degradation (14, 22).
Thus, a decrease in GKRP might have contributed to the
exaggerated decline of hepatic GK protein observed in HFR
dogs and the more modest fall in HFA. Despite the diminished
GK protein and activity, we were unable to detect differences
among groups in hepatic G6P levels.
Glycolytic Flux
The transition from NHLO to uptake is a marker of the
transition from the fed to fasting state, and it occurs 	24 h
after once daily feeding of the diet received by the CTR dogs
(1, 35). All groups were in a state of NHLU during the basal
period because they were underfed relative to their energy
requirements on the day prior to study to achieve similar
fasting states with the three different diet treatments. NHLU
persisted in the HFR group for the duration of the experiment,
whereas the livers of dogs in the other groups switched rapidly
from NHLU to NHLO upon initiation of hyperinsulinemia and
hyperglycemia. In our previous studies (9), dogs fed the HFFD
did not switch from NHLU to NHLO under identical experi-
mental conditions. Thus, it would appear that a selective
increase in dietary fructose elicits greater impairment in net
hepatic glycolytic flux than a selective increase in dietary fat.
However, even in the HFA group, NHLO was significantly
reduced relative to CTR. The impact of the HFA and HFR diets
on lactate metabolism was due possibly to impaired insulin-
mediated activation of rate-limiting enzymes involved in the
glycolytic pathway (phosphofructokinase-1/2 and pyruvate ki-
nase) and/or a decrease in the amount of substrate available for
catabolism through the glycolytic pathway secondary to im-
paired HGU. During the clamp period, arterial blood glycerol
concentrations were higher, and plasma NEFA concentrations
tended to be higher, in the HFA and HFR groups than in CTR.
Chu et al. (7) demonstrated that elevation of plasma NEFA
levels via infusion of lipid emulsion and heparin completely
eliminated the ability of hyperglycemia per se to cause NHLO,
a finding attributable to stimulation of hepatic gluconeogenic
flux and presumably inhibition of glycolysis (2). However, the
similarity in NEFA and glycerol concentrations in HFA and
HFR suggests that this was not the reason, or at least not the
sole reason, for the HFR group’s failure to switch to NHLO
during the clamp.
Insulin Resistance
There was dissociation among diet groups in the present
study with regard to the impact of insulin on phosphorylated
Akt during the clamp. The HFA group exhibited a significant,
albeit modest, decrease in Akt phosphorylation relative to
CTR. In agreement with this finding, the activity ratio of
glycogen synthase, a reflection of its phosphorylation state,
was also significantly reduced in HFA vs. CTR, whereas the
activity ratio of GP tended to be increased. On the other hand,
in HFR, Akt phosphorylation was reduced minimally, and the
GS and GP activity ratios tended to change less than with HFA.
Nevertheless, there was a tendency for GS and GP to be
aberrantly regulated such that when GS and GP were them-
selves expressed as a ratio, there was a significant decrease in
both HFA and HFR vs. CTR. Consistent with this, terminal
liver glycogen levels were significantly reduced in HFR, and
direct glycogen synthesis was reduced in both HFA and HFR
vs. CTR, with HFR impacted more than HFA. These findings
are consistent with the decreases in GK and HGU in these
groups. Thus, high-fat feeding was associated with greater
impairment in Akt phosphorylation and in the covalent regu-
lation of GS and GP than HFR, whereas high-fructose feeding
was associated with greater impairment in hepatic glycogen
synthesis, which was most likely associated with a larger
deficit in GK activity, resulting in insufficient provision of the
substrate required for the synthesis of liver glycogen. On the
other hand, in HFA, changes in the concentrations of allosteric
effectors of GS and GP in vivo could have been sufficient to
partially override covalent inhibition of GS, thereby allowing
some glycogen synthesis. Nevertheless, in our earlier study, the
combination of high dietary fat and fructose under similar
experimental conditions did not result in a further decline in the
activity ratio of GS, a further increase in the activity ratio of
GP, or a greater impairment in hepatic glycogen synthesis (9).
Thus, the relative contributions of fat and fructose to aberrant
hepatic glycogen synthesis are also not additive (Table 3). In
contrast to the marked effects of the modified diets, particularly
HFA and HFR, on hepatic glucose metabolism under hyperin-
sulinemic and hyperglycemic conditions, the nonhepatic tis-
sues appeared to be minimally affected, with no significant
differences among groups in the absolute rates of non-HGU in
either period of the clamp.
Summary and Conclusions
Both HFA and HFR diet consumption for 4 wk significantly
impaired hepatic GK activity, HGU, NHGU, and direct glyco-
gen synthesis. Nevertheless, the HFR diet impacted the mag-
nitude of the decrease in GK activity more than the HFA diet.
Removal of the fructose component from a diet rich in both fat
and fructose ameliorated the severity of the defect in GK
activity, HGU, NHGU, and hepatic glucose disposition; on the
other hand, removal of excess fat in the presence of high
dietary fructose attenuated the severity of the defect in insulin
signaling. Our results are especially important in that they
demonstrate that excess consumption of dietary fat or fructose
per se induces a significant posttranscriptional decrease in GK
protein and an abnormality in liver glucose uptake in a model
in which the finding is not confounded by coincident develop-
ment of gluco- or lipotoxicity (e.g., see Refs. 8, 32, and 45).
These complications can obscure a primary effect of fat and/or
Table 3. Relative responses to the hyperinsulinemic
hyperglycemic clamp
Group 1HGU 2HGP GK Activity GS/GP
Glycogen
Synthesis
CTR 



 



 



 



 




HFA 

 

 

 
 


HFR 
 
 
 

 

HFA 
 HFR* 
 
 
 
 

1HGU and 2HGP, increase in hepatic glucose uptake and decrease in
hepatic glucose production, respectively, under clamp conditions; GK, glu-
cokinase; GS/GP, ratio of glycogen synthase activity to glycogen phosphory-
lase activity. *From our previous publication (9) and shown for reference. 
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 represent the magnitude of the effect, which varies such that

 is the smallest effect. Increasing effects are shown by 
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represents the greatest effect.
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fructose on the liver. In the current studies, circulating and
hepatic triglycerides, as well as fasting plasma glucose, did not
rise in the HFA and HFR groups. Moreover, in previous work
carried out in our laboratory, histological examination of livers
of high-fat-treated dogs revealed little or no fatty infiltration
(Grueter CA and Cherrington AD, unpublished observations).
Thus, our results reflect the impacts of the dietary components
themselves and not the secondary effects of impaired liver
function resulting from fatty infiltration.
Given that rates of HGU under the same experimental
conditions in dogs fed a diet high in both fat and fructose were
similar to those observed in HFR in the present study, as well
as the fact that the sum of the individual effects of HFA and
HFR on HGU, glycogen synthesis, and GK activity exceeded
those in dogs fed the HFFD (9), the adverse effects of high
dietary fat or fructose on the response of the liver to hyperin-
sulinemia, hyperglycemia, and portal glucose delivery do not
appear to be additive. This suggests that the HFA and HFR
diets utilize the same pathway to impair HGU or that they
signal through separate pathways that converge at the same
rate-limiting, saturable step.
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